Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 8/20 | 0.37 |
| ▸ | ADRA1D known ✓ | P25100 | 8/20 | 0.37 |
| ▸ | ADRA1A known ✓ | P35348 | 8/20 | 0.37 |
| ▸ | ADRA1B known ✓ | P35368 | 8/20 | 0.37 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.36 |
| ▸ | AVPR1A known ✓ | P37288 | 2/20 | 0.33 |
| ▸ | AVPR2 known ✓ | P30518 | 1/20 | 0.33 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.32 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.32 |
| ▸ | ALK known ✓ | Q9UM73 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | OXTR | P30559 | 2/20 | 0.33 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.33 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | INSR | P06213 | 1/20 | 0.31 |
| ▸ | NPM1 | P06748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076486 | 0.99 | DRD2 (0.38) | DRD2ADRA1DADRA1AADRA1BGAA | |
| Hydrochloric Acid SCHEMBL1465513 | 0.91 | ALDH1A1 (0.38) | GAALMNAALDH1A1KDM4EAVPR1B | |
| Hydrochloric Acid SCHEMBL1794245 | 0.91 | DRD2 (0.39) | DRD2ADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL1799702 | 0.91 | DRD2 (0.42) | DRD2ADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL1465514 | 0.91 | ALDH1A1 (0.38) | GAALMNAALDH1A1KDM4EAVPR1B | |
| Hydrochloric Acid SCHEMBL1796945 | 0.90 | DRD2 (0.41) | DRD2ADRA1DADRA1AADRA1BKDM4E | |
| Hydrochloric Acid SCHEMBL1464987 | 0.90 | ALDH1A1 (0.35) | GAALMNAALDH1A1KDM4EOXTR | |
| SCHEMBL1464990 | 0.89 | ALDH1A1 (0.36) | GAALMNAALDH1A1KDM4EOXTR | |
| Hydrochloric Acid SCHEMBL1796763 | 0.89 | DRD2 (0.39) | DRD2ADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL1797246 | 0.89 | KDM4E (0.41) | DRD2ADRA1DADRA1AADRA1BGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050959-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBVIE DEUTSCHLAND (DE) | 2017-02-23 | — | — | US | disclosed |
| US-9487505-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-11-08 | — | — | US | disclosed |
| EP-1667993-B1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBVIE DEUTSCHLAND (DE) | 2015-07-01 | — | — | EP | disclosed |
| US-20140187543-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-03 | — | — | US | disclosed |
| US-8580842-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | ABBOTT GMBH & CO. KG (DE) | 2013-11-12 | — | — | US | disclosed |
| EP-2546252-A1 | Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them | Abbott GmbH & Co. KG (DE) | 2013-01-16 | — | — | EP | disclosed |
| US-8350055-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | ABBOTT GMBH & CO. KG (DE) | 2013-01-08 | — | — | US | disclosed |
| US-20110077241-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBOTT GMBH & CO. KG (DE) | 2011-03-31 | — | — | US | disclosed |
| US-20110071156-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBOTT GMBH & CO. KG (DE) | 2011-03-24 | — | — | US | disclosed |
| US-7902379-B2 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them | ABBOTT GMBH & CO. KG (DE) | 2011-03-08 | — | — | US | disclosed |
| US-20070185126-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing Them | AbbVie Deutschland GmbH & Co. KG (DE) | 2007-08-09 | — | — | US | disclosed |
| EP-1667993-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | Abbott GmbH & Co. KG (DE) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005030755-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | ABBOTT GMBH & CO. KG (DE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071156-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | OXTR, AVPR2, AVPR1A | DRD2 17/4885ADRA1D 10/4885ADRA1A 30/4885 |
| US-20140187543-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | OXTR, AVPR2, AVPR1A | DRD2 16/4885ADRA1D 18/4885ADRA1A 35/4885 |
| US-20070185126-A1 | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing Them | OXTR, AVPR2, AVPR1A | DRD2 15/4885ADRA1D 19/4885ADRA1A 34/4885 |
| US-20110077241-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | OXTR, AVPR2, AVPR1A | DRD2 17/4885ADRA1D 10/4885ADRA1A 30/4885 |
| US-20170050959-A1 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | OXTR, AVPR2, AVPR1A | DRD2 16/4885ADRA1D 18/4885ADRA1A 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.